Navigation Links
AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
Date:5/30/2012

REDWOOD CITY, Calif., May 30, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that it has obtained commitments from certain non-affiliated and affiliated institutional investors to purchase approximately $10.0 million of its common stock in a private placement.  AcelRx has entered into a securities purchase agreement with the investors pursuant to which AcelRx will sell an aggregate of 2,922,337 shares of its common stock and warrants to purchase up to 2,630,103 additional shares of common stock.  Each unit, consisting of one share of common stock and one warrant, to purchase 0.9 shares of common stock, will be sold for a purchase price of $3.40 to non-affiliated investors and approximately $3.51 to affiliated investors.  The warrants are exercisable six months after the issuance date at an exercise price equal to $3.40 per share, and will expire five years from the issuance date.  The private placement is subject to customary closing conditions and is expected to close during the week of May 28, 2012. 

Cowen and Company, LLC served as lead placement agent and JMP Securities served as co-placement agent for the transaction.

Proceeds from the private placement are expected to be used for general corporate and working capital purposes, including the development of the ARX-01 Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.

In connection with the private placement, AcelRx has agreed, subject to certain terms and conditions, to file a registration statement under the Securities Act covering the resale of shares of common stock, including shares of common stock underlying the warrants, within
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Marta Rendon, MD, founder of the Rendon Center for Dermatology ... international key opinion leader in dermatology, was one of only ... to attend the international Aesthetic Experts Summit held ... at this gathering of over 600 physicians from 57 countries, ... experts from Asia and ...
(Date:11/24/2014)...  AiCure, an artificial intelligence company providing advanced ... ingestion, has announced the start of a major ... receiving medication as maintenance therapy for opioid addiction. ... have quadrupled in the last 15 years. Opioids ... cocaine and benzodiazepines combined. Overall, the economic cost ...
(Date:11/24/2014)... 2014  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... the board of directors and from his positions as chairman ... recently serving as the company,s president and chief operating officer, ... the board of directors.  Gary Lyons , a member ... Mr. Gower is expected to remain an employee until the ...
Breaking Medicine Technology:Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Can artificial intelligence solve the $55 billion problem of opioid abuse? 2Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3
... FRIMLEY, England, May 20 , - Tasigna(R) ... to Prior Treatment in the Chronic (Early) Phase ... Nature of Tasigna(R) Tackles the Root Cause of ... - Tasigna Expands CML Portfolio for Novartis, ...
... Similar to, Native Bladder by Six Months; Data Presented at May ... ... Session, ORLANDO, Fla. and EAST NORRITON, Pa., May 19 ... and neo-vessels, presented preclinical efficacy data for its,Tengion Neo-Bladder Replacement(TM) at ...
Cached Medicine Technology:Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 2Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 3Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 4Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 5Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2
(Date:11/26/2014)... Obispo, CA (PRWEB) November 26, 2014 ... is offering lower prices in an early celebration of ... Bunion Booties are being offered at the promotional price ... promotional pricing is in addition to any automatic discounts ... the Bunion Bootie website for complete details. ...
(Date:11/26/2014)... News Facts , Lexmark’s ... RSNA 2014 in Chicago. The company will demonstrate ... images, photos, videos and documents found throughout the ... learn more about these innovative medical content management ... initiatives – that enable more informed clinical decisions, ...
(Date:11/26/2014)... -- Youngsters who enter puberty early are at increased ... puberty was linked with a number of factors associated ... levels, according to the researchers. Early puberty was also ... and peers, and having friends who were prone to ... study found an association between early puberty and these ...
(Date:11/26/2014)... -- The number of emergency department visits in the United ... record 136 million in 2011, according to the U.S. Centers ... that fewer people were going to ERs with non-urgent medical ... care within two hours of arriving at the ER. In ... Sixty percent of patients arrived at the ER after ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, ... Nexium may disrupt the makeup of bacteria in the digestive ... a small new study suggests. The research doesn,t ... become ill, and study authors aren,t recommending that anyone stop ... "should be used at the lowest dose that provides adequate ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... in the pancreas, but in the brain as well. When ... can be brain cell death and subsequent development of the ... was conducted in rats, and it was identified that insulin ... produced in the nerve cells, neurons in several brain regions. ...
... of the International Association for Dental Research held in ... a study// that says eating sugar-free yogurt is good ... odor or so called bad breath is caused by ... study revealed that volunteers who had sugar-free more and ...
... in the juice of pomegranate may help in reducing ... process of plaques etc forming in the inner lining ... state of atherosclerosis. This causes disturbed blood flow and ... the risk of atherogenesis. ,The new study ...
... has found out that depression has to be blamed for ... to treat the same. The study was conducted on 60,000 ... results showed both the newer and older classes of antidepressants ... first month of being prescribed.The older class of tricyclic antidepressants ...
... Diabetes Care, March 2005, scientists have reported that caffeine may ... the measure for the risk of heart disease. If a ... risk of heart problems. ,Diabetes type 2 happens when ... As this happens the body becomes unable to produce enough ...
... administration of the drug tezosentan did not improve worsening heart ... // despite high hopes. The above fact was found out ... date. The study was conducted to evaluate if something more ... to speed up hospital discharge and prevent them from coming ...
Cached Medicine News:
... Helmer PC1200 Platelet Incubators ... your laboratory counter top. These ... institution to have the security ... environment without taking up a ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... Platelet incubators hold rotators and ... temperature can be set at ... 15C to 40C (59F to ... from top to bottom. Recorder ...
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: